Mr Harveer Dev
I am a CRUK Clinical Lecturer in the Early Detection Programme, and Honorary Speciality Registrar in Urology, with a research interest in genome stability and prostate cancer.
Mutations in genes like BRCA1 contribute to the development of various diseases including prostate cancer, but these also generate therapeutic vulnerabilities. My research aims are to improve our understanding of these pathways in cancer, and how they relate to disease progression, treatment response and drug resistance in the clinic. This will allow us to better identify and stratify patients to individualised therapies at earlier stages of disease.
BRCA1 BRCA2 PALB2 53BP1 RIF1 MAD2L2 SHLD1 SHLD2 FAM35A C20orf196
Symplectic Elements feed provided by Research Information, University of Cambridge
Dev H et al. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nature Cell Biology. 2018. DOI: 10.1038/s41556-018-0140-1.
Asim M et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nature Communications. 2017 Aug 29;8(1):374. PMID: 28851861.
Dev H et al. Investigating upper urinary tract urothelial carcinomas: a single-centre 10-year experience. World Journal of Urology. 2017 Jan;35(1):131-138. PMCID: PMC5233745.
Dev H et al. Surgical margin length and location affect recurrence rates after robotic prostatectomy. Urologic Oncology. 2015 Mar;33(3):109.e7-13. PMID: 25512161.
Dev H et al. Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies. Journal of Translational Medicine. 2011 Jul 26;9:121. PMID: 21791045.